ライフサイエンスコーパス: lactic

1 Lactic, acetic, citric, succinic, and hydroxycinnamoyl t

2 tween REF and Bio21B breads, while the acids lactic, acetic, phenyllactic, 4-OH-phenyllactic and indo

3 l methods to determine the concentrations of lactic, acetic, propionic and butyric acids in sour cass

4 Lactic acid (2-Hydroxypropanoic acid) is generated from

5 to detect the role of 3, 4-dihydroxyl-phenyl lactic acid (DLA) during ischemia/reperfusion (I/R) indu

6 Lactic acid (LA) is present in tumors, asthma, and wound

7 (BS) of cookies was positively correlated to lactic acid (LA) SRC, DS, peak time, sedimentation value

8 d on oligo-dimethylsiloxane (oDMS) and oligo-lactic acid (oLA), diblock co-oligomers with highly nonc

9 PEG-lactic acid (PEG-LA) nanocarriers were prepared by coval

10 Lactic acid (pH 3.9) treatment combined with passive sen

11 and had no statistical difference from poly lactic acid (PLA) and polycaprolactone (PCL).

12 o encapsulate ATRA in largely uniform poly L-lactic acid (PLLA) microparticles, with the efficiency o

13 l substances like epicatechin (R(2)=0.93) or lactic acid (R(2)=0.87) could be precisely determined ju

14 Intra-arterial administration of lactic acid (to simulate exercising muscle and evoke a p

15 significant, because glycogen depletion and lactic acid accumulation are major causes of muscle fati

16 significant, because glycogen depletion and lactic acid accumulation are two of the major causes of

17 n the rates of muscle glycogen depletion and lactic acid accumulation during submaximal exercise; thi

18 esults in slower rates of glycogenolysis and lactic acid accumulation in muscle during contractile ac

19 s a slowing of muscle glycogen depletion and lactic acid accumulation.

20 a significantly greater pressor reflex than lactic acid alone in the presence of naloxone.

21 significantly greater pressor response than lactic acid alone, while administration of APETx2 inhibi

22 Lactic acid also induced [GAR(+)]-like epigenetic states

23 ed to block the synthesis of the by-products lactic acid and acetic acid, respectively.

24 haracteristics and RS formation, followed by lactic acid and acetic acid.

25 ldol catalyst with a 1,2-HS catalyst enables lactic acid and alkyl lactate formation from ketohexoses

26 ino acids are ubiquitous pseudodipeptides of lactic acid and amino acids that are rapidly formed by r

27 Intra-arterial co-administration of lactic acid and E-2 led to a significantly greater press

28 hether pharmacological postconditioning with lactic acid and hydrogen rich saline can provide benefit

29 d that pharmacological postconditioning with lactic acid and hydrogen rich saline nearly replicates t

30 tudy to investigate the co-administration of lactic acid and hydrogen.

31 ic muscle ischaemia leads to accumulation of lactic acid and other inflammatory mediators with a subs

32 re of C. albicans, through the production of lactic acid and other metabolites.

33 ies tumor cell interiors, and cells pump out lactic acid and protons to maintain intracellular pH, ac

34 sensor for the simultaneous determination of lactic acid and pyruvic acid.

35 The acid modification was performed with 3% lactic acid and the oxidation was performed with 1.5% ac

36 [GAR(+)], and did not require utilization of lactic acid as a carbon source.

37 we identify the common bacterial metabolite lactic acid as a strong [GAR(+)] inducer.

38 Lactic acid assay and pH measurement were conducted to s

39 unistic fungal pathogen Candida albicans and lactic acid bacteria (LAB) are common members of the mic

40 Lactic acid bacteria (LAB) are the common probiotics.

41 Lactic acid bacteria (LAB) are the most common beer-spoi

42 Cereal-associated Lactic Acid Bacteria (LAB) are well known for homopolyme

43 opments in synthetic biology have positioned lactic acid bacteria (LAB) as a major class of cellular

44 Although the anti-aging effects of lactic acid bacteria (LAB) have been observed in nematod

45 he function of cell-free solutions (CFSs) of lactic acid bacteria (LAB) on tyramine and other biogeni

46 This research investigated the influence of lactic acid bacteria (LAB) strains on ester levels in Bo

47 In the present study 45 lactic acid bacteria (LAB) strains were isolated from Fe

48 verages produced from fermentation using six lactic acid bacteria (LAB) strains.

49 ility spectrometry (GC-IMS) to differentiate lactic acid bacteria (LAB) through target identification

50 activities as ascertained in the presence of lactic acid bacteria (LAB).

51 lined, but, on the contrary, the quantity of Lactic Acid Bacteria and Bifidobacterium sp. increased c

52 Microbiological (lactic acid bacteria and probiotic Lactobacillus casei 0

53 The cell viability of lactic acid bacteria and yeast was evaluated.

54 Exopolysaccharides produced by lactic acid bacteria are extensively used for food appli

55 Lactic acid bacteria are known to suppress filamentation

56 in oesophageal adenocarcinoma (p=0.028), and lactic acid bacteria dominated the microenvironment in s

57 ties, delaying total aerobic mesophilic, and lactic acid bacteria growth, especially in samples with

58 Lactic acid bacteria have been isolated from living, har

59 of the essential contribution of non-starter lactic acid bacteria in ripening-related activities.

60 aureus and Escherichia coli, maintaining the lactic acid bacteria population ( approximately 100%).

61 he aim of this work is to explore the use of lactic acid bacteria to reduce the amount of mercury sol

62 are the largest cyclic peptides produced by lactic acid bacteria to suppress growth of other bacteri

63 Glucansucrase enzymes of lactic acid bacteria use sucrose to catalyze the synthes

64 n VOC profiles were also observed due to the lactic acid bacteria used as starter cultures, with diff

65 However, significant growth of lactic acid bacteria was observed in this group.

66 Throughout the brining period, lactic acid bacteria were always present while staphyloc

67 In many Lactobacillales species (i.e. lactic acid bacteria), peptidoglycan is decorated by pol

68 and protect bioactive substances, including lactic acid bacteria, due to their physicochemical prope

69 Lactic acid bacteria, mainly lactococci, were the predom

70 ermine), as well as microbiological profile (lactic acid bacteria, total number of microorganisms, ye

71 part of complexes that do not interact with lactic acid bacteria.

72 etween them and other commercially important lactic acid bacteria.

73 combining PPEs with milk and fermented with lactic acid bacteria.

74 ntify at high efficiencies edited cells in a lactic acid bacterium.

75 oncentration of monocarboxylic acid ligand l-lactic acid by varying the ratio of Zn(2+) to ligand fro

76 Transient exposure to lactic acid caused yeast cells to heritably circumvent g

77 ory cytokine IL-17, whereas in CD8+ T cells, lactic acid causes the loss of their cytolytic function.

78 s, enabling ten-fold increased production of lactic acid compared to titres obtained with the commonl

79 Lactic acid concentration of sourdough breads prepared w

80 roup, phospholipid, protein, amino acid, and lactic acid content was significantly lower for smokers

81 t were monitored included alcoholic proof, l-lactic acid content, glucose+fructose and acetic acid co

82 In contrast, we find the lactic acid effect on CD8+ T cell motility to be indepen

83 further explore and validate the blockade of lactic acid export as an anticancer strategy, we disrupt

84 c pathways has concentrated on improving the lactic acid fermentation parameters, enhancing the acid

85 ble hydrogels provided controlled release of lactic acid for several hours; however, a maximum releas

86 The production of lactic acid has been associated with contributing to the

87 reased flux to hydroxycinnamates is syringyl lactic acid hexoside.

88 n and nuclear magnetic resonance as syringyl lactic acid hexoside.

89 ed a similar improvement in stability during lactic acid hydrogenation to propylene glycol in the pre

90 ications, real-time 3D OCT imaging of pH and lactic acid in the anterior chamber of a fish eye was re

91 Extracellular sodium lactate and lactic acid inhibit the motility of CD4+ and CD8+ T cell

92 showed statistically inhibitor effect since lactic acid inhibited microbial growth, decreased pH qui

93 Elevated lactic acid level secondary to ischemia of the bowel wal

94 as result of malolactic fermentation and the lactic acid levels reached values between 0.40 and 0.96

95 ositive blood cultures, vasopressors, and/or lactic acid levels.

96 the rice starches treated with citric acid, lactic acid or acetic acid were significantly reduced as

97 thylsiloxane block and a crystalline oligo-l-lactic acid or oligomethylene block.

98 The lactic acid pathway and the central carbon metabolism of

99 In this regard, l-lactate/lactic acid permeability has been shown for various isof

100 n was recorded in M-red UBF for ascorbic and lactic acid pretreatment (r = -0.031; r = -0.137).

101 ve correlation for Mabonde UBF in citric and lactic acid pretreatment (r = 0.999, p < 0.01; r = 0.985

102 Here we show that lactic acid produced by tumour cells, as a by-product of

103 g techniques and strategies for manipulating lactic acid producing organisms developed to address and

104 Lactobacilli are non-spore forming, lactic acid producing, gram-positive rods.

105 actic acid production noticeably, especially lactic acid production in the 5% DMADDM group, which dec

106 groups slowed the pH drop and decreased the lactic acid production noticeably, especially lactic aci

107 address and overcome major challenges in the lactic acid production process.

108 sed ATP production, glucose consumption, and lactic acid production.

109 Lactic acid racemization is involved in lactate metaboli

110 ation high-molecular-weight amorphous poly-l-lactic acid scaffolds have the potential to improve the

111 al stem cells from the dental pulp on poly-l-lactic acid scaffolds in nude mice gave rise to perfect

112 e malic acid, succinic acid, citric acid and lactic acid solutions, any coloration was mainly due to

113 Lactic acid solvent retention capacity (LASRC), sediment

114 lic shift leads to an enhanced production of lactic acid that decreases extracellular pH (pHe), a hal

115 transporter MCT1 is a passive transporter of lactic acid that has attracted interest as a target for

116 rriers were prepared by covalently attaching lactic acid to 8-arm PEG-SH via cleavable thioester bond

117 Some bacteria use lactic acid to communicate with yeast cells.

118 the tooth surface and consequently produces lactic acid to degrade the tooth's enamel.

119 at pharmacologic inhibitors of MCT1-mediated lactic acid transport may not effectively prevent metast

120 eutectic solvent (DES) based on glucose and lactic acid was considered as extraction solvent for phe

121 ver, a maximum release of only 10%-14% bound lactic acid was observed possibly due to steric hindranc

122 In this study, lactic acid was tested as a signaling molecule in C2C12

123 -coated poly(lactic-co-glycolic acid)/poly(L-lactic acid) (HA-PLGA/PLLA) scaffolds.

124 Poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-b-PLA) micelles and poly(D,L-lactic-co

125 Poly(ethylene glycol)-block-poly(d,l-lactic acid) (PEG-b-PLA) micelles are nanocarriers for p

126 odegradable poly(ethylene glycol)-b-poly(D,L-lactic acid) (PEG-b-PLA) micelles.

127 ialized in packaging materials based on poly(lactic acid) (PLA) due to its eco-friendly nature.

128 Poly(lactic acid) (PLA) is a biodegradable polymer prepared b

129 aded microspheres were formulated using poly(lactic acid) (PLA) to release brimonidine at a constant

130 Using poly(L-lactic acid) (PLLA) as the model polymer, we show that c

131 thin films of biodegradable polymer poly(D,L-lactic acid) and enzyme lipase were used as a model syst

132 Poly(lactic acid) featuring the new gradient isotactic multib

133 ded on 85% porous nonwoven spunbonded poly(l-lactic acid) fiber mesh scaffolds.

134 nd quercetin during the production of poly(l-lactic acid) films with potential to deliver these flavo

135 Three poly(l-lactic acid) formulations with 17.7, 39.6 and 39.1mg/g o

136 the kinetics of ROMP of polystyrene and poly(lactic acid) MMs initiated by (H2IMes)(pyr)2(Cl)2Ru hori

137 e, we investigated the cellular fate of poly(lactic acid) nanoparticles presenting different surface

138 rmination of curcumin encapsulated in poly(l-lactic acid) nanoparticles.

139 rylate), poly(lactic-co-glycolic acid), poly(lactic acid) NPs, liposomes and inorganic systems.

140 oaded into nanoparticles (NPs) made of poly (lactic acid) poly (ethylene glycol) block copolymer (PLA

141 ide-conjugated poly(ethylene glycol)-co-poly(lactic acid) polymeric micelle (RGD-M) that carried a st

142 ynamics of PBS, poly(butylene adipate), poly(lactic acid), and poly(ethylene terephthalate) in assays

143 by PEG-b-PLA micelles, monodisperse oligo(l-lactic acid), o(LA)8 or o(LA)16, has been coupled onto P

144 heres-loaded with AL (CH/nHA-AL) into poly(L-lactic acid)/nanohydroxyapatite (PLLA/nHA) matrix to pre

145 , C3, and C4 products such as glycolic acid, lactic acid, 2-hydroxy-3-butenoic acid, 2,4-dihydroxybut

146 While we detected changes in lactic acid, alanine, glutamine, and glutamate as expect

147 ction, oxygen consumption rates, glycolysis, lactic acid, and ATP production in LMCs.

148 er lipid, phospholipid, protein, amino acid, lactic acid, and nucleic acid content was noted in the s

149 Significant variations in lipid, amino acid, lactic acid, and nucleic acid content were found between

150 Gram staining, acid-fast staining, and lactic acid, cryptococcal antigen, histoplasma antigen,

151 monomers derived from the metabolome (e.g., lactic acid, dihydroxyacetone, glycerol, fumarate) gives

152 dc = 1,4-benzenedicarboxylic acid, l-lac = l-lactic acid, dmf = N,N'-dimethylformamide) and observed

153 ing SO2, methanesulfinic acid, pyruvic acid, lactic acid, ethanesulfinic acid, propanesulfenic acid,

154 The combination of lactic acid, glucose and 15% water (LGH-15) was selected

155 We found that 8 extracellular compounds (lactic acid, nicotinamide, 5-oxoproline, xanthine, hypox

156 f aerobic glycolytic intermediates including lactic acid, pyruvate and the subsequently increased bio

157 The strong production of acetic and lactic acid, the decrease of potentially pathogenic bact

158 ed production of reactive oxygen species and lactic acid, which can be beneficial to cancer growth bu

159 The enzyme interconverts d- and l-lactic acid, which is important for the assembly of cell

160 Twenty-three BMS (3.0x12 mm) and 36 lactic acid-based bioresorbable scaffolds (BRS, 3.0x11 m

161 The Absorb everolimus-eluting poly-L-lactic acid-based bioresorbable vascular scaffold (BVS)

162 ing, high-molecular-weight, amorphous poly-l-lactic acid-based BRS (Amaranth BRS).

163 ultrahigh molecular weight amorphous poly-l-lactic acid-based BRS (APTITUDE, Amaranth Medical [AMA])

164 evaluate a new drug-free fully bioresorbable lactic acid-based scaffold designed to allow early disma

165 Their synthesis starts from l-lactic acid-derived propargyl alcohol, which is submitte

166 and -2 (E-2), modulate ASIC currents and the lactic acid-mediated pressor reflex.

167 rphins in modulating ASIC function to effect lactic acid-mediated reflex increase in arterial pressur

168 orphins by which the opioids can enhance the lactic acid-mediated reflex increase in arterial pressur

169 commercial probiotics (VSL#3) enriched with lactic acid-producing bacteria triggers a protective imm

170 ial injection of alpha,beta-methylene ATP or lactic acid.

171 tastasis beyond its role as a transporter of lactic acid.

172 ing the local pH to 5.0 or less by producing lactic acid.

173 n per os and an intraperitoneal injection of lactic acid.

174 , of which 87% was contributed by formic and lactic acid.

175 emical composition and pH conditions using a lactic acid/lactate buffer system.

176 these community state types are dominated by lactic-acid producing Lactobacillus spp. while the fifth

177 lated to anode respiration (Geobacteraceae), lactic-acid production (Lactobacillales), and syntrophic

178 s with congenital sensorineural deafness and lactic acidemia in association with combined respiratory

179 ivity, severe endurance defects, and chronic lactic acidemia, recapitulating some clinical symptoms d

180 ction, bacteremia, inflammatory markers, and lactic acidemia.

181 Lactic acidosis (LA) frequently occurs after heart trans

182 , it is known to induce metformin-associated lactic acidosis (MALA), a severe medical condition with

183 <1%) patient in the doxorubicin alone group (lactic acidosis [n=1]).

184 An infant presented with fatal infantile lactic acidosis and cardiomyopathy, and was found to hav

185 drome patients in having intermittent severe lactic acidosis and early-onset neurodevelopmental probl

186 Both affected individuals presented with lactic acidosis and evidence of multiple mitochondrial r

187 All case subjects presented with lactic acidosis and nine developed hypertrophic cardiomy

188 Mitochondrial myopathy with lactic acidosis and sideroblastic anemia (MLASA) is an o

189 suggestive of mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrom

190 MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) and MIDD syndr

191 Metformin poisoning with lactic acidosis appears to be amenable to extracorporeal

192 The first presented with acute lactic acidosis at 3 weeks of age and developed severe d

193 Lactic acidosis developed during continuous infusion of

194 or patients with critical tissue hypoxia and lactic acidosis due to anemia.

195 Among children with lactic acidosis due to severe anemia, transfusion of lon

196 pertaining to metformin, kidney disease, and lactic acidosis in humans between 1950 and June 2014.

197 Data suggesting an increased risk of lactic acidosis in metformin-treated patients with chron

198 cultures with concurrent vasopressors and/or lactic acidosis increased (P < .001 for all methods), wh

199 Linezolid-induced lactic acidosis is associated with diminished global oxy

200 cultures with concurrent vasopressors and/or lactic acidosis remained stable (P = .098).

201 fection who all presented with severe type B lactic acidosis shortly after starting treatment with om

202 h a clinical spectrum ranging from infantile lactic acidosis to childhood (cardio)myopathy and late-o

203 No cases of lactic acidosis were observed.

204 cs, increased glycolysis, glutaminolysis and lactic acidosis, and neurotransmitter imbalances.

205 ssociated with a clinical triad of myopathy, lactic acidosis, and sideroblastic anemia in predominant

206 tients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes.

207 , including mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS).

208 Severe symptoms include seizures, lactic acidosis, cardiac arrhythmia, and death within da

209 ated individuals who presented at birth with lactic acidosis, hypotonia, feeding difficulties, and de

210 epatic metabolism, intestinal infarction and lactic acidosis.

211 mplex II deficiency, were found to have mild lactic acidosis.

212 and CotH expression, an effect not seen with lactic acidosis.

213 gram, marked elevation of serum enzymes, and lactic acidosis.

214 year-old man who died with linezolid-induced lactic acidosis.

215 and serologic evidence of liver failure and lactic acidosis.

216 ab work was significant for leukocytosis and lactic acidosis.

217 aprevir-ritonavir-dasabuvir may cause type B lactic acidosis.

218 out sourdough, with levels of acetic and d/l lactic acids in dough and bread baking significantly hig

219 The effects of two common organic acids; lactic and acetic acids (150 mg/kg) on physicochemical p

220 al molecules often decrease pHo by secreting lactic and other carboxylic acids, we studied how pHo in

221 n of arginine did not constitute a hurdle to lactic and probiotic bacteria survival, with presented v

222 , cells accumulated an intracellular pool of lactic and pyruvic acids, magnified by the MCT1 inhibito

223 tivity of serum, increased the ratio between lactic and total aerobic bacteria, increased water-holdi

224 Patients with lactic and unmeasured anions acidosis, but not those wit

225 efficient and food-grade enzymatic lysis of lactic bacteria (Oenococcus oeni) in white and red wine.

226 TTB did not exhibit any undesired effect on lactic bacteria which are necessary for development of a

227 ertain anthocyanin ratios, oxalic, shikimic, lactic, citric and succinic acids, sugars like glucose,

228 ess were observed, as well as an increase in lactic, citric, and acetic acid contents.

229 amide)-carboxymethyl chitosan shell and poly lactic-co-glycolic acid (PLGA) core for enhancing locali

230 ed on the self-healing capacity of poly (DL)-lactic-co-glycolic acid (PLGA) microspheres containing g

231 devices compare favourably with current poly-lactic-co-glycolic acid fixation systems, however, silk-

232 ng ligands into a drug-encapsulating Poly dl-lactic-co-glycolic acid polymer (PLGA), via a double emu

233 While poly(ethylene glycol)-block-poly(lactic-co-glycolic acid) (PEG-PLGA) copolymers have been

234 ly, biodegradable poly(ethylene glycol)-poly(lactic-co-glycolic acid) (PEG-PLGA) microparticles were

235 rmulated particulate nanocarriers using poly(lactic-co-glycolic acid) (PLGA) and PLGA-polyethylene gl

236 ic matrix consisting of water-insoluble poly(lactic-co-glycolic acid) (PLGA) and water-soluble polyvi

237 r hybrid nanoparticles (CSLPHNPs) with poly (lactic-co-glycolic acid) (PLGA) core and lipid layer con

238 Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable FDA a

239 d within the scaffolds and accommodated poly(lactic-co-glycolic acid) (PLGA) microparticulate systems

240 Here, two poly(lactic-co-glycolic acid) (PLGA) microsphere formulations

241 into lipid microtubes and NEP1-40 into poly (lactic-co-glycolic acid) (PLGA) microspheres, obviating

242 d nanoparticles (LPNs) consisting of poly(DL-lactic-co-glycolic acid) (PLGA) nanocarriers modified wi

243 he study was to evaluate the ability of poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NP) to en

244 y, encapsulation of the compound within poly(lactic-co-glycolic acid) (PLGA) nanoparticles (PLGA-EtNB

245 E2 and NS3 proteins formulated in poly-(D, L-lactic-co-glycolic acid) (PLGA) nanoparticles adjuvanted

246 Here we demonstrate that poly(lactic-co-glycolic acid) (PLGA) nanoparticles carrying r

247 Poly(lactic-co-glycolic acid) (PLGA) nanoparticles containing

248 Copolymer poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded wit

249 - and CMI-inducing adjuvant based on poly(dl-lactic-co-glycolic acid) (PLGA) nanoparticles modified w

250 ght to test how surface modification of poly(lactic-co-glycolic acid) (PLGA) nanoparticles with pepti

251 microgels encapsulated with drug-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles.

252 Fluorescently-tagged poly(lactic-co-glycolic acid) (PLGA) NPs were loaded with BOD

253 ) as an alternative surface coating for poly(lactic-co-glycolic acid) (PLGA) NPs.

254 t to test the hypothesis that inhalable poly(lactic-co-glycolic acid) (PLGA) particles of sildenafil

255 Poly (lactic-co-glycolic acid) (PLGA) supplies lactate that ac

256 t, we describe microspheres composed of poly(lactic-co-glycolic acid) (PLGA) that can encapsulate IPV

257 PEI1.8k was blended with poly(lactic-co-glycolic acid) (PLGA) to enhance electrostatic

258 r "barcoding" nanoparticles composed of poly(lactic-co-glycolic acid) (PLGA) with bright, spectrally

259 e was chosen as a model therapeutic and poly(lactic-co-glycolic acid) (PLGA) with similar molecular w

260 repared by encapsulation of the drug in poly(lactic-co-glycolic acid) (PLGA), a polymer that is used

261 f polymers with distinct functions: (i) poly(lactic-co-glycolic acid) (PLGA, P) serving as the main d

262 d)-block-polyethylene glycol)-block-poly(D,L-lactic-co-glycolic acid) (PLGA-b-PEG-b-PLGA) sol-gels ha

263 )-block-poly(ethylene glycol)-block-poly(d,l-lactic-co-glycolic acid) (PLGA-b-PEG-b-PLGA) thermosensi

264 illamine (SNAP) was encapsulated within poly(lactic-co-glycolic acid) 50:50 (PLGA) microspheres by us

265 ically relevant parameters, we report a poly(lactic-co-glycolic acid) based curcumin nanoparticle for

266 ated that carboxyl functionalization of poly(lactic-co-glycolic acid) can achieve great material homo

267 Dexamethasone-releasing PLGA poly(lactic-co-glycolic acid) microsphere/PVA (polyvinyl alco

268 Dexamethasone-releasing poly(lactic-co-glycolic acid) microspheres/polyvinyl alcohol

269 imiR-21) encapsulated in biodegradable poly (lactic-co-glycolic acid) nanoparticles (PLGA-NP), admini

270 carriers such as FDA approved pegylated poly(lactic-co-glycolic acid) nanoparticles (PLGA-PEG-NP) has

271 nut oral immunotherapy using CpG-coated poly(lactic-co-glycolic acid) nanoparticles containing peanut

272 damage as compared to similarly sized poly (lactic-co-glycolic acid) particles.

273 s three distinct compartments namely; poly(l-lactic-co-glycolic acid) polymeric core acting as a drug

274 -dimensional (3D)-printed biodegradable poly(lactic-co-glycolic acid) scaffolds (PLGA), and hydroxyap

275 coating on a well-studied biodegradable poly(lactic-co-glycolic acid) support membrane.

276 Biocompatible poly (lactic-co-glycolic acid) was selected as the polymer she

277 roparticle formulations as well as with poly(lactic-co-glycolic acid)(PLGA)-based microparticles, co-

278 od; PEG = poly(ethylene glycol); PLGA = poly(lactic-co-glycolic acid)) assembled from small AuNRs (di

279 rs consist of poly(butylcyanoacrylate), poly(lactic-co-glycolic acid), poly(lactic acid) NPs, liposom

280 Nanoparticles composed of poly(lactic-co-glycolic acid), with polyethylene glycol coati

281 he effect of thermosensitive hydrogels (poly(lactic-co-glycolic acid)-b-poly(ethylene glycol)-b-poly(

282 adium(II) dichloride in a biocompatible poly(lactic-co-glycolic acid)-b-polyethyleneglycol platform.

283 ing and solubilization of EpoB in a poly(d,l-lactic-co-glycolic acid)-block-poly(ethylene glycol)-blo

284 ctic acid) (PEG-b-PLA) micelles and poly(D,L-lactic-co-glycolic acid)-block-polyethylene glycol)-bloc

285 en co-cultured on hydroxyapatite-coated poly(lactic-co-glycolic acid)/poly(L-lactic acid) (HA-PLGA/PL

286 lycolic acid)-b-poly(ethylene glycol)-b-poly(lactic-co-glycolic acid); PLGA-PEG-PLGA) for increasing

287 Self-healing of pores in Poly(lactic-co-glycolic acid)s (PLGA) plays an important role

288 Poly(d,l-lactic-co-glycolic) acid (PLGA) nanoparticles containing

289 tor 4 (TLR4) and TLR7/8 encapsulated in poly(lactic-co-glycolic) acid (PLGA)-based nanoparticles (NPs

290 SCs incorporated in a uniquely designed poly(lactic-co-glycolic) acid scaffold, a clinically safe pol

291 overcome this limitation, electrospun poly (lactic-co-glycolide) (PLGA) mats, which have excellent b

292 ctrospun composite coating comprised of poly(lactic-coglycolic acid) (PLGA) nanofibers embedded in a

293 veloped a nontoxic transfection vector: poly(lactic-coglycolic acid) nanoparticles that release siRNA

294 composed of end-to-end linkages between poly(lactic-coglycolic acid)-b-poly(ethylene glycol) (PLGA-b-

295 In this article, we describe a poly-lactic-coglycolic acid-based NP platform, wherein avidin

296 determine carboxylic acids (acetic, formic, lactic, malic and succinic acids), amino acids (alanine,

297 r alcohols significantly suppress strawberry/lactic/red fruity, coconut/wood/vanilla and humidity/TCA

298 nd functional properties were studied at two lactic to glycolic acid ratios (50:50 and 65:35).

299 also compared the mortality of patients with lactic, unmeasured anions, and hyperchloremic metabolic

300 phenyllactic, 4-OH-phenyllactic and indole-3-lactic were present only in Bio21B breads.